otlertuzumab   Click here for help

GtoPdb Ligand ID: 9951

Synonyms: CD37-SMIP [8] | TRU-016 | TRU016
Immunopharmacology Ligand
Compound class: Antibody
Comment: Otlertuzumab (TRU-016) is a monospecific, humanized anti-CD37 antibody-like protein that is being investigated as a clinical therapeutic for various form of lymphoma [4,6-7]. Otlertuzumab was developed using Aptevo's modular ADAPTIRTM platform.
Immunopharmacology Comments
CD37 is an immuno-oncology target that is being evaluated for the treatment of B cell malignancies, including non-Hodgkin lymphoma, and CLL [6].
Immunopharmacology Disease
Disease X-Refs Comment References
non-Hodgkin lymphoma Disease Ontology: DOID:0060060
OMIM: 605027
Phase 1 clinical candidate for NHL- see NCT00614042 and NCT01317901.
B-cell lymphoma Disease Ontology: DOID:707
Phase 1b clinical candidate for indolent B-cell small lymphocytic lymphoma. 2
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
Phase 1 clinical candidate for CLL- see NCT01644253. 1